Ligand Pharmaceuticals INC Form 4 insider transactions

Ligand Pharmaceuticals Inc. Director John L. LaMattina was granted 1,209 restricted stock units and 5,783 non-qualified stock options on June 6, 2025, as part of his compensation.

Martine Zimmermann, a Director at Ligand Pharmaceuticals Inc., acquired 1,209 restricted stock units and 5,783 non-qualified stock options as part of her compensation, while also having 188 shares withheld for tax liabilities.

Ligand Pharmaceuticals Inc. Director Stephen L. Sabba was granted 1,209 restricted stock units and 5,783 non-qualified stock options on June 6, 2025, as part of his compensation.

Ligand Pharmaceuticals Inc. Director John W. Kozarich was granted 1,209 restricted stock units and 5,783 non-qualified stock options on June 6, 2025, as part of his compensation.

Ligand Pharmaceuticals Inc. Director Jason Haas has reported the acquisition of 1,209 restricted stock units and 5,783 non-qualified stock options, granted by the Board of Directors on June 6, 2025.

LIGAND PHARMACEUTICALS INC's Chief Legal Officer and Secretary, Andrew Reardon, reported recent and future stock transactions, including tax-related share withholdings and a planned sale under a 10b5-1 trading plan.

John W. Kozarich, a Director at Ligand Pharmaceuticals Inc., exercised stock options to acquire 2,406 shares of common stock at $52.3 per share, increasing his direct beneficial ownership to 46,181 shares.

Ligand Pharmaceuticals' CEO, Todd C. Davis, recently acquired additional shares of the company's common stock through a series of transactions.

Octavio Espinoza, CFO of Ligand Pharmaceuticals, reports purchasing 1,500 shares of common stock on May 9, 2025.

Director Stephen Sabba reports acquisition of common stock and exercise of non-qualified stock options in Ligand Pharmaceuticals.

Andrew Reardon, CLO & Secretary of Ligand Pharmaceuticals, reports acquisition of common stock and stock options.

Octavio Espinoza, CFO of Ligand Pharmaceuticals, reported selling 5,000 shares of common stock and receiving a grant of 32,717 employee stock options.

CEO Todd Davis reports acquisition of restricted stock units and stock options in Ligand Pharmaceuticals.

CEO Todd C. Davis reports acquisition and disposal of Ligand Pharmaceuticals stock due to vesting of performance stock units and tax liabilities.

Octavio Espinoza, CFO of Ligand Pharmaceuticals, reports acquisition and disposal of common stock related to vesting of performance and restricted stock units.

Andrew Reardon, CLO & Secretary of Ligand Pharmaceuticals, reports acquisition and disposal of common stock related to vesting of performance and restricted stock units.

Ligand Pharmaceuticals' Chief Financial Officer, Octavio Espinoza, sold 2,104 shares of common stock at a weighted average price of $116.3738 on December 23, 2024.

Ligand Pharmaceuticals' Chief Financial Officer, Octavio Espinoza, sold 1,859 shares of common stock to cover tax liabilities related to the settlement of restricted stock units.

Director John L. LaMattina exercised stock options and sold shares of Ligand Pharmaceuticals on November 27, 2024.

Andrew Reardon, CLO & Secretary of Ligand Pharmaceuticals, exercised stock options and sold 2,000 shares of common stock on September 23, 2024.

Octavio Espinoza, CFO of Ligand Pharmaceuticals, reported the sale of common stock on September 20, 2024, according to a Form 4 filing with the SEC.

Matthew Korenberg, President & COO of Ligand Pharmaceuticals, reports exercising stock options and selling shares on September 20 and 23, 2024.

Octavio Espinoza, CFO of Ligand Pharmaceuticals, exercised stock options at prices of $57.22 and $80.72 on September 17, 2024.

Matthew Korenberg, President & COO of Ligand Pharmaceuticals, reports exercising stock options and disposing of shares to cover tax obligations on September 16, 2024.

Octavio Espinoza, CFO of Ligand Pharmaceuticals, executed stock options at prices of $57.22 and $70.04, resulting in the acquisition of 753 shares of common stock.

Andrew Reardon, CLO & Secretary of Ligand Pharmaceuticals, exercised stock options and sold shares on August 28, 2024.

Matthew Korenberg, President & COO of Ligand Pharmaceuticals, recently sold shares of the company's common stock in a series of transactions.

Matthew E. Korenberg, President and COO of Ligand Pharmaceuticals, sold 18,245 shares of common stock on August 9, 2024.

Ligand Pharmaceuticals CEO Todd C. Davis purchased 2,500 shares of common stock at a price of $97.3922 per share on August 8, 2024.

Andrew Reardon, Chief Legal Officer of Ligand Pharmaceuticals, acquired 329 shares of common stock through the company's Employee Stock Purchase Plan on June 28, 2024.